These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 4852505)
41. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. Toda A; Uehara S; Inoue T; Utoh M; Kusama T; Shimizu M; Uno Y; Mogi M; Sasaki E; Yamazaki H Xenobiotica; 2018 Jul; 48(7):720-726. PubMed ID: 28686070 [TBL] [Abstract][Full Text] [Related]
42. International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB Nurse Pract; 1995 Sep; 20(9):15-6, 21-2. PubMed ID: 7501312 [TBL] [Abstract][Full Text] [Related]
43. Inhibition of warfarin activity by ribavirin. Schulman S Ann Pharmacother; 2002 Jan; 36(1):72-4. PubMed ID: 11816263 [TBL] [Abstract][Full Text] [Related]
44. A model solution for intestinal absorption of warfarin. A drug with non-linear distribution pharmacokinetics in the rat. Julkunen RJ; Kekki M; Wahlström B Arzneimittelforschung; 1980; 30(2):264-7. PubMed ID: 7378103 [TBL] [Abstract][Full Text] [Related]
47. Enhancement of warfarin-induced hypoprothrombinemia by triclofos. Sellers EM; Lang M; Koch-Weser J; Colman RW Clin Pharmacol Ther; 1972; 13(6):911-5. PubMed ID: 5081604 [No Abstract] [Full Text] [Related]
48. Parmacokinetic analysis of the effect of barbiturate on the anticoagulant action of warfarin in man. Levy G; O'Reilly RA; Aggeler PM; Keech GM Clin Pharmacol Ther; 1970; 11(3):372-7. PubMed ID: 5445741 [No Abstract] [Full Text] [Related]
49. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Breckenridge A; Orme M; Wesseling H; Lewis RJ; Gibbons R Clin Pharmacol Ther; 1974 Apr; 15(4):424-30. PubMed ID: 4821443 [No Abstract] [Full Text] [Related]
50. The effect of oxyphenbutazone on the excretion of 14 C-warfarin in the bile of rat. Wosilait WD; Eisenbrandt LL Res Commun Chem Pathol Pharmacol; 1972 Sep; 4(2):413-20. PubMed ID: 5074533 [No Abstract] [Full Text] [Related]
53. Prothrombin levels maintained with meprobamate and warfarin. A controlled study. Gould L; Michael A; Fisch S; Gomprecht RF JAMA; 1972 Jun; 220(11):1460-2. PubMed ID: 4623950 [No Abstract] [Full Text] [Related]
54. Investigation of patients with abnormal response to warfarin. Bentley DP; Backhouse G; Hutchings A; Haddon RL; Spragg B; Routledge PA Br J Clin Pharmacol; 1986 Jul; 22(1):37-41. PubMed ID: 3741725 [TBL] [Abstract][Full Text] [Related]
55. Kinetics of drug action in man. Levy G Acta Pharmacol Toxicol (Copenh); 1971; 29 Suppl 3():203-10. PubMed ID: 5316402 [No Abstract] [Full Text] [Related]
56. The plasma half-lives of the enantiomers of warfarin in warfarin-resistant and warfarin-susceptible rats. Hewick DS J Pharm Pharmacol; 1972 Aug; 24(8):661-2. PubMed ID: 4403752 [No Abstract] [Full Text] [Related]
57. Studies on the interaction of warfarin and clofibrate in man. O'Reilly RA; Sahud MA; Robinson AJ Thromb Diath Haemorrh; 1972 Apr; 27(2):309-18. PubMed ID: 4340370 [No Abstract] [Full Text] [Related]
59. The second reported kindred with hereditary resistance to oral anticoagulant drugs. O'Reilly RA N Engl J Med; 1970 Jun; 282(26):1448-51. PubMed ID: 4192578 [No Abstract] [Full Text] [Related]
60. Management of acute deep venous thrombosis. Satiani B Am Fam Physician; 1982 Apr; 25(4):103-9. PubMed ID: 7064760 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]